MSD ECL binding assays

KR Katharina Röltgen
SN Sandra C.A. Nielsen
OS Oscar Silva
SY Sheren F. Younes
MZ Maxim Zaslavsky
CC Cristina Costales
FY Fan Yang
OW Oliver F. Wirz
DS Daniel Solis
RH Ramona A. Hoh
AW Aihui Wang
PA Prabhu S. Arunachalam
DC Deana Colburg
SZ Shuchun Zhao
EH Emily Haraguchi
AL Alexandra S. Lee
MS Mihir M. Shah
MM Monali Manohar
IC Iris Chang
FG Fei Gao
VM Vamsee Mallajosyula
CL Chunfeng Li
JL James Liu
MS Massa J. Shoura
SS Sayantani B. Sindher
EP Ella Parsons
ND Naranjargal J. Dashdorj
ND Naranbaatar D. Dashdorj
RM Robert Monroe
GS Geidy E. Serrano
TB Thomas G. Beach
RC R. Sharon Chinthrajah
GC Gregory W. Charville
JW James L. Wilbur
JW Jacob N. Wohlstadter
MD Mark M. Davis
BP Bali Pulendran
MT Megan L. Troxell
GS George B. Sigal
YN Yasodha Natkunam
BP Benjamin A. Pinsky
KN Kari C. Nadeau
SB Scott D. Boyd
request Request a Protocol
ask Ask a question
Favorite

Plasma samples from vaccinees and COVID-19 patients were heat-inactivated at 56°C for 30 minutes and tested using multiplexed ECL detection in a 96-well plate format with MSD® V-PLEX® serology panels and instrumentation according to the manufacturer’s instructions. V-PLEX COVID-19 Coronavirus Panel 2 kits were used to detect IgM, IgG, and IgA antibodies to SARS-CoV-2 N, S1 NTD, RBD, and spike antigens and to spike proteins of SARS-CoV-1 and other HCoVs including HCoV-OC43, HCoV-HKU1, HCoV-NL63, and HCoV-229E. V-PLEX SARS-CoV-2 Panel 9 and 11 kits were used to determine IgG antibody concentrations and RBD-ACE2 blocking antibody percentages to different SARS-CoV-2 variant RBDs, with Alpha, Beta, Gamma, Epsilon, Kappa, Eta/Iota, B.1.526.2, P.3 and Wuhan-Hu-1 present in both panel 9 and 11, and with B.1.214.2 in panel 9 and Delta in panel 11. V-PLEX SARS-CoV-2 Panel 20 kits were used to determine IgG antibody concentrations to Alpha, Beta, Gamma, Delta, and Wuhan-Hu-1 SARS-CoV-2 variant spike proteins. Plasma samples were analyzed in duplicate at a 1:5,000 (for IgG binding assays) or a 1:10 (for RBD-ACE2 blocking assays) dilution in MSD diluent. Coronavirus-specific antibodies were detected with anti-human IgM, IgG, or IgA antibodies, or indirectly with human ACE2 protein (for RBD-ACE2 blocking assays) conjugated to SULFO-TAG™ ECL labels and read with a MESO® QuickPlex® SQ 120 instrument. Cutoff values for positive antibody test results for Wuhan-Hu-1 antigens were determined by the manufacturer based on sera from 200 pre-pandemic healthy adults and 214 PCR-confirmed COVID-19 patients. We tested an additional 37 healthy adult pre-pandemic plasma specimens to evaluate the manufacturer’s cutoff values, and to determine cutoffs for positive binding to variant virus antigens, defined as the mean plus three standard deviations of the results from the pre-pandemic specimens. Antibody binding ratios for Wuhan-Hu-1 and viral variant antigens were only calculated for specimens that were above the cutoff values for positive results. Saliva samples were analyzed in duplicate at a 1:5 dilution in MSD diluent 2. Each plate contained duplicates of a 7-point calibration curve with serial dilution of a reference standard, a blank well and three positive control samples. Calibration curves were used to calculate antibody unit concentrations by backfitting ECL signals measured for each sample to the curve.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A